Mazyar Shadman, MD, Fred Hutchinson Cancer Research Center, Seattle, WA, comments on the possibility of using zanubrutinib in patients who are intolerant to ibrutinib and/or acalabrutinib. Dr Shadman explains that zanubrutinib led to a lower rate of adverse events, including in patients who remained on zanubrutinib for a longer period of time than with ibrutinib and acalabrutinib. This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.